Can antidepressants prevent interferon-alpha-induced depression? A review of the literature

General Hospital Psychiatry

Volumn 32, Issue 4, 2010, Pages 401-405

  Almeida, Amanda Galvão de ^a,b   Guindalini, Camila ^b   Batista Neves, Susana ^a   de Oliveira, Irismar R ^a   Miranda Scippa, Ângela ^a   Quarantini, Lucas C ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antidepressant; Interferon alpha; Major depression; Prevention; Review

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; PAROXETINE; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; INCIDENCE; MAJOR DEPRESSION; MELANOMA; RELAPSE; RETINA HEMORRHAGE; RISK REDUCTION; VISUAL IMPAIRMENT; CHEMICALLY INDUCED; DEPRESSIVE DISORDER;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; HEPATITIS C; HUMANS; INTERFERON-ALPHA; PAROXETINE;

EID: 77954620563     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.03.001     Document Type: Article

References (35)

1. Capuron L., Gumnick J.F., Musselman D.L., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26(5):643-652.
2. Asnis G.M., De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006, 40(4):322-335.
3. Asnis G.M., De la Garza R., Kohn S.R., et al. IFN-induced depression: a role for NSAIDs. Psychopharmacol Bull 2003, 37(3):29-50.
4. Hauser P., Soler R., Reed S., et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000, 41(5):439-441.
5. Keefe B. Interferon-induced depression in hepatitis C: an update. Curr Psychiatry Rep 2007, 9(3):255-261.
6. Arora A., Attwood J. Common skin cancers and their precursors. Surg Clin North Am 2009, 89(3):703-712.
7. Morasco B.J., Rifai M.A., Loftis J.M., et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007, 103(1-3):83-90.
8. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56(11):819-824.
9. Quarantini L.C., Bressan R.A., Galvao A., et al. Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int 2007, 27(8):1098-1102.
10. Raison C.L., Woolwine B.J., Demetrashvili M.F., et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007, 25(10):1163-1174.
11. Hunt C.M., Dominitz J.A., Bute B.P., et al. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997, 42(12):2482-2486.
12. Forton D.M., Taylor-Robinson S.D., Thomas H.C. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006, 18(4):333-338.
13. Quarantini L.C., Miranda-Scippa A., Batista-Neves S., et al. A neuropsychological study comparing patients infected with HCV and HBV without psychiatric comorbidities. J Med Virol 2009, 81(7):1184-1188.
14. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999, 340(16):1228-1233.
15. Quarantini L.C., Miranda-Scippa A., Batista-Neves S., et al. The effect of early virological response in health-related quality of life in HCV-infected patients. J Med Virol 2008, 80(3):419-423.
16. Hauser P., Khosla J., Aurora H., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7(9):942-947.
17. Kraus M.R., Schafer A., Schottker K., et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008, 57(4):531-536.
18. Gleason O.C., Fucci J.C., Yates W.R., Philipsen M.A. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C - A pilot study. Dig Dis Sci 2007, 52(10):2557-2563.
19. Musselman D.L., Lawson D.H., Gumnick J.F., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344(13):961-966.
20. Schaefer M., Schwaiger M., Garkisch A.S., et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005, 42(6):793-798.
21. Kraus M.R., Schäfer A., Al-Taie O., et al. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005, 12(1):96-100.
22. Robaeys G., Wichers M.C., De Bie J., et al. Does antidepressant medication in patients with hepatitis C undergoing interferon alpha treatment reduce therapeutic efficacy?. Gut 2009, 58(1):145.
23. Kraus M.R., Schäfer A., Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001, 345(5):375-376.
24. Kessler R.C., Berglund P., Demler O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):593-602.
25. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):617-627.
26. Dalton S.O., Johansen C., Mellemkjaer L., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003, 163(1):59-64.
27. Quarantini L.C., Miranda-Scippa A., Schinoni M.I., et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol 2006, 29(3):138-143.
28. Cuijpers P., van Straten A., Smit F., et al. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. Am J Psychiatry 2008, 165(10):1272-1280.
29. Dbouk N., Arguedas M.R., Sheikh A. Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci 2008, 53(4):1100-1106.
30. Raison C.L., Borisov A.S., Broadwell S.D., et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005, 66(1):41-48.
31. Ozkan M., Corapcioglu A., Balcioglu I., et al. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med 2006, 36(3):283-297.
32. Batista-Neves S.C., Quarantini L.C., de Almeida A.G., et al. High frequency of unrecognized mental disorders in HCV-infected patients. Gen Hosp Psychiatry 2008, 30(1):80-82.
33. Bull S.J., Huezo-Diaz P., Binder E.B., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2008.
34. Kraus M.R., Al-Taie O., Schafer A., et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132(4):1279-1286.
35. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009, 65(4):344-348.